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This paper is about medical treatment of endometriosis. The main medical treatment 
is hormonal therapy in order to suppress endometrial tissue inflammation. Pain is 
managed through non steroidal anti-inflammatory drugs and opioids. Alternative 
treatment is also helpful.  
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INTRODUCTION !!
Endometriosis is defined as the presence of endometrial tissue 
outside the uterus. It is qualified as a benign disease, even though it is 
one of the most important cause of abdominal pain and infertility1. The 
pathophysiology is poorly understood, in consequence diagnostic and 
treatment are a long way of being improved. 
Available medical treatment include hormonal drugs (combined oral 
hormonal contraceptives, progestins, gonadotropin releasing hormone 
agonists, danazol, aromatase inhibitors), and alternative treatment 
(acupuncture, diet, ….) 
This paper will provide an overview of the current medical treatments 
used for symptomatic endometriosis. !!!
1. HISTORY !
Symptoms of Endometriosis have been described since the 1800’s 
century, but we could presume that this disease was around since a 
longer time2. During the Hippocrates time, young women were described 
with chronic abdominal pain. In the Middles Ages, these women were 
thought to be punished by God by having done unacceptable behaviour, 
resulting in this pain. Unfortunately these are only speculations since the 
only way to get proof of ectopic endometrial tissue is through surgery and 
precisely by getting histological parameter of the tissue sampled. 
The first (published) person that notified endometriotic tissue on the 
ovary was W.W Russell, in 1898: “on the microscopic study of the ovary, 
we were astonished to find areas which were an exact prototype of the 
uterine glands and interglandular connective tissue.”3 
Sampson, a gynecologist at The Albany Medical Hospital (New York 
State), became fascinated by this disease and gave the name “chocolate 
cyst” of the endometrioma. At that time, he estimated the prevalence of 
being 10 % of the reproductive women population5.  !
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2. EPIDEMIOLOGY !
Sampson’s estimated prevalence of endometriosis was not far from 
today’s actual numbers. Surgery being the diagnosis apparatus, true 
prevalence is unknown, but we estimate that around 5 to 10% of women 
get affected by endometriosis in their reproductive years (from 15 to 49 
years old)5. Hundred and seventy-six Millions of women are diagnosed, 
leaving millions of other undiagnosed women, (approximately 1 billion of 
reproductive women population). 
Many different studies detected several risk factors for 
endometriosis2,6:  
- early menarche,  
- polymenorrhea (menstruation cycle less than 27 days), 
- menorhagia (duration of menses more than seven days), 
- increases with the number of years since last childbirth ,  
- heavy consumption of alcohol and caffein,   
- prenatal exposure to diethylstilbestrol, 
- inverse relationship to parity, 
- hypoxia and iron deficiency may contribute to early onset, 
!
Several protective factors are also detected:   
- increased body mass,   
- pregnancy,   
- parity,   
- prolonged period of lactation,   
- regular exercises,   
- smoking2,6. 
!
!
Women in their reproductive age are the principal group affected. 
Mean age for diagnosis is between 25 to 35 years old ( 27 being the 
average)2. This supports the fact that endometriosis is related to 
hormones. Cases of endometriosis in pre-menarcheal girls or post-
menopausal women have also been reported with frequency around 12% 
among pre-menarchal and 2-5% in postmenopausal women. In girls under 
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17 years endometriosis is frequently associated with Mullerian anomalies 
following cervical and/or vaginal obstruction, while in post-menopausal 
women with oestrogen therapy2  
 The reported prevalence of endometriosis among asymptomatic 
patients seeking elective sterilisation is between 3 and 45 %7. 
!
!
!
2. PATHOPHYSIOLOGY 
!
THEORIES 
The search for underlying mechanism behind development of 
endometriosis took years. Back in the days, Sampson was surprised by 
the histologic nature of the cyst he discovered. He found that this tissue 
was similar to the one of uterine endothelium. Those similarities made him 
“create” one of the etiological theory of endometriosis: the retrograde 
theory.4 
In a 5 years period, he collected  293 cases of women with 
endometriosis . During surgery he visualised menstrual blood retrogradely 
passing through the fallopian tubes and lining in to the peritoneal cavity4. 
It has been proposed that  endometriosis is caused by the seeding or 
implantation of endometrial cells. 
Retrograde menstruation is observed in 75 to 90 % of the 
laparoscopy performed on women having there menses and those 
numbers are higher among women with endometriosis2. Endometrial cells 
can be grown in vitro in cell culture, and even in vivo after being implanted 
beneath abdominal skin of chimpanzee.2.  
Transplantation theory can not explain existence of endometriotic 
tissue outside the peritoneal cavity (lungs, pleura..), neither why pre-
menarcheal girls can be affected and why cases of men were observed2. 
The other theory states that foci of peritoneal endometriosis might be 
“due to some specific irritant present in the cyst contents which stimulates 
the peritoneal endothelium to a metaplasia with the development of 
endometrial tissue typical both in structure and function”2. The idea behind 
metaplastic (coelomic) theory it is that metaplasia may occur in coelomic 
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epithelium (derived from Mullerian ducts cells, ovarian mesenchymal stroll 
cells, gonad somatic cells and testicular interstitial cells). Metaplasic 
process is induced by activation of an oncogenic K ras allele8. Metaplastic 
theory can explain situations that are not supported by the transplantation 
theory. It explains endometriosis in sites like thumb, knee, tights, that had 
disintegrated coelomic epithelium adjacent to the mesenchymal limb buds 
during early embryogenesis2. There are also reports of men treated with 
very high dose of oestrogen to treat andropause who developed 
endometrial cells in their abdominal walls or urinary bladder2. This has 
been also shown in vitro by cultivating ovarian surface epithelium, stromal 
cells and oestradiol in a collagen gel lattice form endometrial glands and 
stroma2. 
Another theory implies that vascular and lymphatic dissemination of 
endometrial cells may occur as well as direct seeding during invasive 
procedures like Cesarean section, pelvic surgery or episiotomy 2 
!
!
GENETIC FACTORS 
A genetic basis for the disorder has been suggested by familial 
clustering cases. There is a 6 to 9 times fold increase risk of 
endometriosis in 1st degree relative compared with general population. A 
relative risk of 7,2 is observed between mothers and sisters2.  !!
IMMUNOLOGIC FACTORS AND INFLAMMATION 
When looking for autoantibody, we see a high prevalence of antinuclear 
antibodies directed against endometrial antigen, more specifically against 
transferrin and laminin2. Those findings support the idea that there is some local 
chronic inflammatory process going on in the peritoneal cavity of these patients. 
This impaired immune functions have many actors. Progesterone has the 
capacity of balancing the endocrine/ immune physiology of the endometrium 
tissue. In endometriotic tissue, there is a failure of the progesterone to act 
appropriately. Indeed, these women seem to secrete normal progesterone level 
but their endometrium’s respond is reduced. It does not display the changes in 
specific gene and protein expression normally expressed during the 
pregesterone-dominated secretory phase of the menstrual cycle9. Macrophages 
and monocytes in peritoneal fluid are numerous. Instead of gatekeepers 
                                                                                                                                    4
protectors, they seem to promote the disease by secreting growth factors and 
cytokines that stimulate proliferation of ectopic endometrium2. Interleukin-8 
seems to correlate with the severity of the disease. It is elevated in women with 
severe disease condition2. Some studies pointed out the impaired function of 
retinoid activity in women affected by endometriosis. The effect relationship is 
still unknown but in model system, retinoid activity decreases pro-inflammatory 
cytokines while increasing anti-inflammatory proteins like IL-1010.  !!
MOLECULAR MECHANISMS 
!
Mechanism of pain 
Pain is the most common symptom in endometriosis. Aside with 
infertility, relieving pain is the gold standard of endometriosis treatment. 
Mechanism of pain associated with endometriosis is very complex. It 
is proposed to occur through 3 mechanisms: 
- directly and indirectly form focal bleeding of endometriotic 
epithelium 
- local inflammation 
- irritation or infiltration of pelvic nerves2. 
All three mechanisms oftenly exist in synergy The local inflammation 
and the bleeding will make adhesion formation, resulting in fibrotic 
thickening which results in painful traction of physiologic tissue1.In 
patients with pain endometriosis stage is oftenly not related to pain 
symptoms. Some women with advanced endometriosis have little pain or 
in contrary mild disease presents with excruciating pain. Pain stays a 
subjective and inter personal symptoms. 
!
Mechanism of infertility: Long term consequence 
An association between endometriosis and infertility is generally 
accepted and prevalence  ranges from 20 to 40 % in those women2. 
Studies reported a lower spontaneous monthly fecundity rate (total 
number of pregnancies by the number of month of pregnancy exposure). 
It is oftenly associated with tuboovarian adhesions and disturbed 
anatomy. Also, excess production of prostaglandin, metalloproteinase, 
cytokines and chemokines is probably part of the process, through a 
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chronic inflammation that can impair the physiologic functions of 
folliculogenesis, fertilisation and implantation1. Even in the field of in vivo 
fertilisation process, a meta analysis revealed lower implantations and 
pregnancy rates among women with endometriosis2. It could be a 
reflection of poor oocyte quality. Indeed, experiences with oocyte donation 
from women with Endometriosis shows higher incidence of arrested and 
abnormal development of the embryos2. 
!
!
3. SYMPTOMS  
!
The two most common symptoms of endometriosis are chronic 
pelvic pain and infertility. Thirty to forty-four percent of infertile women are 
diagnosed with endometriosis. Pain mainly depends on the area affected. 
Dysmenorrhea, irregular or heavy bleeding, pelvic pain, power back pain, 
dyspareunia (worsened in the premenstrual phase), are the most 
representative one2.  
Bladder and colon can be affected resulting in dyschezia, inguinal pain, 
dysuria, hematuria.. Pulmonary involvement can be presented with 
hemoptysis. Diaphragm lesions can cause reflected pain in the right 
shoulder. Brain lesions can cause catamenial seizures. Umbilicus implant 
display with umbilical bleeding. Approximately one third of them remain 
asymptomatic6.  
!
!
!
4. DIAGNOSIS 
!
!
It is well recognised that a delay from symptoms to the diagnosis of 
endometriosis exists. Studies report an overall diagnostic delay of 10 
years in Germany and Austria, 8 years in the UK and Spain, 7 years in 
Norway, 7-10 years in Italy and 4-5 years in Ireland and Belgium7. 
However since endometriosis highly affects QoL the patients awareness 
on diagnosis is rising7. 
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CLINICAL 
The severity of the disease does not correlate with the number and 
severity of the symptoms2. Clinical informations are not sufficient for 
diagnosis. Bases on studies and expert opinion, the Guideline 
Development Group (GDG) recommends clinicians to consider the 
diagnosis of endometriosis:  
- in the presence of gynaecological symptoms such as: 
dysmenorrhoea, non-cyclical pelvic pain, deep dyspareunia, infertility 
and fatigue in the presence of any of the above; 
- in women of reproductive age with non-gynaecological cyclical 
symptoms (dyschezia, dysuria, haematuria and rectal bleeding, 
shoulder pain)7. 
Clinical exam also guides you toward endometriosis. Again, the 
GDG recommends clinicians to consider following: 
- the diagnosis of deep endometriosis in women with painful 
induration and/ or nodules of the rectovaginal wall found during clinical 
examination or visible vaginal nodules in the posterior vaginal fornix; 
- the diagnosis of ovarian endometrioma in women with adnexal 
masses detected during clinical examination; 
- the diagnosis of endometriosis in women with positive history for 
symptoms mentioned above, even if the clinical examination is normal7.   
!
!
CA-125  
CA-125 is a cell surface antigen expressed by derivatives of 
coelomic epithelium. CA-125 marker has a good specificity but low 
sensitivity in detecting endometriosis. A meta analysis that tested 
sensitivity and specificity of this marker using surgery based diagnosis of 
endometriosis concluded a 90 % specificity, but a 30 % sensitivity. It 
cannot be used as a screening/diagnostic test, but could help 
differentiating an ovarian endometrioma from a benign cyst. Also a 
sustained  level of CA-125 after endometriosis surgery is a factor of bad 
prognosis2.  
!
!
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IMAGING 
Transvaginal ultrasonography (TVUS) is first line of imaging method 
as it can detect ovarian endometriomas with a 90 % specificity and almost 
a 100 % sensitivity. However,TVUS is not a good tool in distinguishing 
pelvic adhesions from superficial disease. Another barrier is that it is 
highly operator dependent7. Transrectal ultrasonography ameliorates 
discovering a deep infiltrating structures (endometriotic lesions of the 
bladder, uterosacral ligament, recto-vaginal septum). MRI has 70 % 
sensitivity and 75 % specificity. MRI is useful in distinguishing between 
acute hemorrage (isointense T1 and hypo intense T2) and blood products 
(hypointense T1 and T2). It could detect only 30-40% of lesions observed 
in surgery2. 
!
!
SURGICAL DIAGNOSIS BY LAPAROSCOPY IS THE GOLD 
STANDARD TOOL 
Surgical diagnosis by laparoscopy represents the gold standard for 
diagnosis. Examination should include a careful and complete inspection 
and palpation in a clockwise or counterclockwise fashion with a blunt 
probe of the bowel, bladder, uterus, tubes, ovaries, cul-de sac and broad 
ligament1. To avoid any under diagnosis, this procedures should not be 
performed during 3 months of hormonal treatment2. The classical image 
looks like blue black “powder burn” in the middle of fibrotic plaque. 
However those are the less frequent findings. Implants can have various 
aspects. Red lesions would represent an early stage being vascularised 
and proliferative. Advanced disease’s lesions are characterised being 
pigments. Both types are metabolically active in comparison with the less 
vascularised white lesions which are often asymptomatic and of fortuite 
findings. White lesions represent lower activity and metabolism, which is 
not correlated to symptom severity. Differential diagnosis of those lesions 
are endosapingiosis, mesothelial hyperplasisia, hemosiderin deposition, 
hemangiomas, adrenal rests, inflammatory changes or splenosis1,2. 
Biopsies of any lesion found on laparoscopy are performed for differential 
diagnosis. Histologic criterias (mitotic activity, vascularisation…) confirm 
approximatively 60% of endometriosis2. Ovarian puncture and aspiration 
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can be helpful when no specific macroscopic characteristics are found in 
endometrioma. 
A negative diagnostic laparoscopy seems to be highly accurate for 
excluding endometriosis7. 
The GDG recommends that clinicians: 
- perform a laparoscopy to diagnose endometriosis, although 
evidence is laking that a positive laparoscopy “without histology” proves 
the presence of disease; 
- confirm a positive laparoscopy by histology, since positive 
histology confirms the diagnosis of endometriosis even though negative 
histology does not exclude it7. 
!
!
CLASSIFICATION 
Classification criteria and staging is crucial for improvement of the 
management of endometriosis and predicting the outcome. The most 
widely used is the classification by the American Society of Reproductive 
Medicine, in 1996. This classification includes appearance, size, depth of 
peritoneal and ovarian implants; the presence, extent, type of adnexal 
adhesions, the degree of cul de sac obliterations, morphology of the 
implants (red, white, black)1,2. Only the women who have undergone 
surgery can be evaluated by this classification. Stages are graded from I 
to IV, respectively from minimal to severe affectation2.  
!
!
!
!
!
!
!
!
!
!
!
!
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!
Figure 1: The American Fertility Society revised classification of 
endometriosis 2 
Annexe A 
!
!
!
!
                                                                                                                                    10
!!
!
Figure 2: The American Fertility Society revised classification of 
endometriosis2  
Annexe B 
!
!
!
!
!
!
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In 2010, Adamson and Pasta, (two specialist fertilization doctors), 
created another surgical classification resulting from a retrospective 
cohort study, which is the Endometriosis Fertility Index (EFI). It adds the 
historical score ( factors as age, number of infertility year and previous 
pregnancies), and the surgical score ( functions of fallopian tubes, 
fimbriae and ovaries). The final EFI score is placed in a graph with the 
time in month in the x axis and the percentage of being pregnant in y axis. 
The EFI score predicts predicts cumulative pregnancy rates over 3 years, 
going from 0 to 10, 0 representing the poorest and 10 the best prognosis. 
For example, if a woman has a EFI score of 6, she has 20 % chance of 
being pregnant in 6 months. This form is used as a tool for developing 
treatment plans in infertile patients2. 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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!
!
!
Figure 3: Endometriosis Fertility Index (EFI) surgery form 
!
!
!
!
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TREATMENT  
!
Classifications used for diagnosis of endometriosis in women have a 
main goal to help improve treatment plans for patients with endometriosis. 
Endometriosis treatment is patient dependant. It is administrated 
according to the pain and to the infertility which impede the most on 
quality of life2. Of course, before starting medical treatment, other causes 
of pelvic pain symptoms should be considered7. Also, if a patient doesn’t 
respond well to medical treatment, a la-parascopy is performed to find 
further signs7.  In more than 50 % of patients, endometriosis will progress 
through their life. Early treatment, even with mild symptoms, might be 
beneficial. Surgical treatment should be reserved for severe stages, but 
even in minimal to mild endometriosis, it offers a little improvement in the 
fertility outcome. 
Focusing more on the medical treatment, the population we are 
interested in are patients desiring pain relief with or without definitive 
surgical diagnosis. Medical treatment does not seem to improve fertility, 
and it is not effective for endometriomas and pelvic adhesions2. Knowing 
what we know about the pathophysiology of this disease, the goal of the 
treatment is to reduce or eliminate menstruations, which will, not only help 
with the acute situation, but also will decrease the chance of getting new 
endometrial implants2. Therefore, hormonal treatment acts directly by 
treating the aetiology, and consequently the pain. Pure analgesic drugs 
will help as treating the symptomatic patients with pain as leading 
symptom. Pain relief is managed through pure analgesic drugs and 
through drugs decreasing the endometrial tissue, as we said above, that 
is responsible for inflammation and pain.  
!
!
!
!
! !
!
!
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!
!
!
!
!
Figure 4: Management of pain associated with suspected 
endometriosis 
According to: Leyland N et al (2010) S10. 
!
!
!
!
!
!
!
!
!
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1. COMBINED HORMONAL CONTRACEPTIVES 
!
Combined hormonal contraceptives (COC) are the cornerstones of 
medical endometriosis treatment. The debate still exist between taking 
COCs continuously or cyclic. Studies have been conducted without 
proving superiority of one over another1. This concept of suppressing the 
physiologic hormonal rhythm was introduced by Robert Kistner, an 
American gynaecologist who specialised in the treatment of 
endometriosis1.  
!
A continuous administration (1 pill per day), for 6 to 12 months will 
induce a state of “pseudopregnancy”. The oestrogen component can 
potentially stimulates endometrial tissue growth with increasing symptoms 
for the first weeks1.  Amenorrhea and decidualization of endometrial tissue 
(some evidence  of inducting apoptosis of the tissue) are effective in 
reducing the pain2.  
As much as 75 to 90 % of women experience pain relief 2.  It also reduce 
retrograde flow, thus limiting spreading of the disease1. The lower 
effective dose should be 30 microgram of ethinyl oestradiol1. 
Unfortunately this treatment only seems to silence the condition. A 
recurrence rate of 17% is observed during the first year after stoping the 
COCs1.  COCs should remain the first line in treatment of woman with 
mild pain symptoms without plans for pregnancy at that moment. Most 
common sides effects associated with oestrogen or progestin include: 
premenstrual syndrome, migraine, breast tenderness, menstrual 
irregularities, abdominal discomfort, mood lability. Most serious 
complication of COC use are thromboembolitic events that can be 
avoided by determining potential risk in each patient6. A variety of 
biological parameters have to be checked within three months of 
treatment. Glycemia on fasting, complete blood count, triglyceridemia and 
cholesterol level6. Contra-indications are: personal history of 
thromboembolytic events (arterial or veinous), migraine with aura, 
hormone dependant cancer (breast, endometrial), tobacco use more than 
15 cigarettes per day if over 35 years old, non treated hypertension 
(systole > 160 mmHg and/or diastole > 100 mmHg), thrombophilia, 
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hypercholesterolemia > 8 mmol/l, morbid obesity (BMI > 39), pregnancy, 
breast feeding < 6 weeks post partum, ischemic cardiomyopathy, valvular 
cardiomyopathie with complications, stroke, active viral hepatitis, severe 
hepatitis insufficiency12. 
The GDG advise clinicians to7 
- consider prescribing a combined hormonal contraceptive, as it 
reduces endometriosis-associated dyspareunia, dysmenorrhoea and 
non-menstrual pain; 
- consider the continuous us of combined oral contraceptive pill in 
women suffering from endometriosis-associated dysmenorrhea; 
- consider the use of vaginal contraceptive ring or a transdermal 
(oestrogen/ progestin) patch to reduce endometriosis-associated 
dysmenorrhoea, dyspareunia and pelvic pain 
!
!
2. PROGESTINS 
!
Progestins have been used for treating endometriosis since the 
19501. Oral progestins are effective and cheap in treating endometriosis 
and their efficacy has been proven by many studies1. A randomized 
controlled study compared a cylic 21days contraception (20 microgram 
ethynil estradiol and with desogestrel 0.15mg), combined with danazol 
(50mg per day), versus medroxypogesterone acetate ( MPA 150mg every 
3 months) observed superiority of MPA for the relief of dysmenorrhea: 
72,5% versus 57,5%12.  
This superiority is due to the power of inhibiting the pituitary gland 
when high dose is administered, leading to an ovulation and thus 
amenorrhea. High dose of progestins also shows suppression of 
endometrial matrix metalloproteinase2. 
A single randomised controlled trial comparing high doses of MPA 
(100mg/day for 6 months) and placebo found that fifty percent of the 
progestins group presented with complete remission of the visible 
endometrial tissue versus 12% in the placebo group13. Side effects are 
nausea, weight gain,fluid retention, breast tenderness, irregular bleeding 
(up to 40 % but easily controlled by estradiol 2 mg / day for 7 to 10 days), 
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depression (5%. One of the main reason to discontinuous medication)2. 
Progestins can also decrease HDL level ( which is risk factor for 
cardiovascular diseases)2.  At the dose needed to suppress the 
hypothalamo-pituiatry-ovarian axis, four percent of the spinal bone 
mineralisation is depleted after 6-12months treatment but without any 
pathological fractured observed and a rapid recover is seen after 
discontinuing the treatment2.  
A variety of progestins are available. There is no particular clinical 
trials evidence showing that one progestin is more suitable than another1. 
MPA can be given intramuscularly every 3 months. At a dose of 150 
mg, it also decreases pain. This progestin induce a profound amenorrhea 
and anovulation with which the body has trouble recreating a physiologic 
cycle, and thus needing a long recovery period if the patient desires a 
pregnancy1.  
NETA (2.5 mg/day) is effective in reducing the intensity of pain in 
women with deep infilitrating endometriosis (Surgical versus low-dose 
progestin treatment for endometriosis-associated severe deep 
dyspareunia II: effect on sexual functioning, psychological status and 
health-related quality of life14. !
Other form, like the 52mg levonorgestrel-releasing intra uterine 
device, is of great use regarding deep infiltrating recto-vaginal 
endometriosis, reducing its volume as well as reducing dysmenorrhea, 
dyspaneuria and pelvic pain. This intra-uterine device can stay in place for 
up to 5 years1,2.  
Gestrinome is a 19 nortestosterone derivative with androgenic, 
antiprogestagenic, antiestrogenic, and antigonadotropic properties. The 
androgenic effect acts centrally and peripherally. It leads to an increase of 
free testosterone and also reduces sex hormone binding globulin levels. 
The anti-estrogenic effect reduces estradiol levels as down as in the early 
follicular phase. The anti-gonadotropic effect reduces LH . Those overall 
effects cause cellular inactivation and degradation of the endometric 
implants. As we can assume, amenorrhea appears, but is dose 
dependent. This drug has a 28 hours long half life when orally taken. The 
standard posology is 2,5 mg twice a week. In a multi-centered, double 
blind study, comparing Gestrinone and GnRH, with reducing pelvic pain 
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as the primary goal, showed non significant difference. Side effects of 
Gestrinone include nausea, muscle cramps, weight gain, acne, 
seborrhoea and oily skin and hair. One of the main precaution using this 
drug is contraception to avoid pregnancy which can have effect on the 
masculinisation of the foetus1.  
Dienogest is an oral progestin that has been investigated extensively 
in the treatment of endometriosis in two clinical programs performed in 
Europe and Japan, including dose-ranging, placebo-controlled, active 
comparator-controlled, and long-term (up to 65 weeks) studies. These 
studies demonstrated that dienogest 2 mg daily effectively alleviates the 
painful symptoms of endometriosis, reduces endometriotic lesions, and 
improves indices of quality of life. Dienogest showed a favorable safety 
and tolerability profile in these studies, with predictable adverse effects, 
high rates of patient compliance, and low withdrawal rates15. 
The GDG advise the use of progestagins to reduce endometriosis-
associated pain7.  
!
!
3. GnRH AGONIST 
!
Gonadotropin releasing hormones agonists are a modified version of 
native GnRH. Chemically, a switch of the L-amino acid to the D-amino 
acid makes this drug resistant to degradation, thus increasing its half life 
(3 to 8 hours) and time of receptor occupancy in the pituitary gland. This 
constant stimulation of GnRH receptors causes, after initial “flare up”, a 
down regulation of receptors concentration2. Down regulation of receptors 
creates a ‘pseudo menopausal” state. Deprivation of oestrogen results in 
amenorrhea, preventing new peritoneal seeding2. Furthermore, GnRH 
receptors are present in ectopic endometrium. Direct inhibition was shown 
in in-vitro models. Another potential action decreases adhesion formation 
(causing pain). This effect was proven in in-vivo rat models, through a 
decrease of plasminogen activators and matrix MMPs1.  
A variety of GnRH agonists are available: leuprolide, buserelin, 
nafarelin, histrelin, goserelin, deslorelin, and triptorelin. An inconvenient 
fact about those drugs is that they are ineffective orally and must be taken 
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either intramuscularly, subcutaneously or intra-nasally1. After two months 
of treatment, almost 100 % of women are in a pseudo-menopausal state 
with pain release2. There are several side effects associated with GnRH 
treatment: hot flashes, vaginal dryness, decrease libido, depression, 
irritability, fatigue, head ache, change in skin texture changes associated 
with hypogonadism. Hypogonadal state rises a risk for bone mineral 
depletion especially after 6 months of treatment mostly in the lumbar 
spine and the femoral neck. It can be up to 1% per month. Although, 
mineralisation slowly recovers after treatment discontinuation in most 
women, it is not the case for all women. In order to prevent bone loss 
“add-back” therapy is used adding a progestins or a combination of 
progestin/oestrogen. A minimum of 30 to 45 pg / mL of serum oestrogen 
should be maintained. Ones can wonder why adding oestrogen when we 
know that it is causing endometriosis symptoms. The “oestrogen treash-
hold hypothesis’, sustains that the oestrogen level needed to counter back 
vasomotor state and mineral bone loss in the hypo-oestrogenic state 
associated with GnRH use is much lower than the level causing 
endometriosis signs. Nevertheless, adding only oestrogen to the GnHR 
agonist therapy showed increase in pelvic pain. Combinations of 
oestrogen and progestin are available. A 0,625 mg conjugated 
oestrogen's with 2,5 mg medroxyprogesterone acetate; or with 
norethindrone acetate, 5mg ; or oestradiol, 2 mg, with norethisterone 
acetate 1mg. Progestine only can reduce the side effect of bone loss, 
using noresthisterone with a higher posology from 1,2 mg to 5 mg, 
tibolone 2,5 mg, bisphosphonate ( cyclic etidronate using 400 mg daily for 
2 weeks every 2 months, or alendronate 10 mg daily), also option of the 
selective oestrogen receptor modulator: raloxifene, 60 mg per day. Other 
progestins do not prevent bone loss1,2.  
After cessation of GnHR agonist + add back therapy or GnHR 
agonist alone, pain relapses is 10 to 20 % per year, with a cumulative 
recurrence rate after 5 years of 55 %2. In another report, mineral bone 
density if not fully recovered even after 6 years or terminating the therapy, 
and the add back regime did not reverse this process. In this way, GnHR 
agonists should not be prescribed to women that had not reach there full 
bone density1.  
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Opposite to this “add- back” therapy, the “draw back” therapy 
consists of a single GnHR Agonist: the nafarelin for a 6 months treatment 
at 400 micro gram/ day. It has shown to be equally competent with lower 
bone loss1.  
Clinicians are recommended to use GnRH agonists as one of the 
options, although evidence is limited regarding dosage or duration of 
treatment and with careful considerations in young women and 
adolescents7.  
!
!
4. GnRH ANTAGONIST 
!
Recently introduced, GnRH antagonists induce a competitive 
inhibition of the GnRH receptors on the cell membrane of the 
gonadotropic cell. It suppress FSH, LH and consequently oestrogen 
secretion without inducing the flare effect16. Cetrorelix is administered 
subcutaneously at the dosage of 3 mg within 8 weeks. In this study, 100 
% of the patients were symptoms free during the treatment, but the power 
of the study can be questioned, only 15 persons were studied. Adverse 
effects are headache and urterine bleeding3.  
A  relatively new agent elagolix was studied in a study consisting of 3 
groups of 252 women with surgical diagnosis of endometriosis that were 
treated with 150 mg elagolix ( GnRH antagonist), 75 mg elagolix or an 
active control: DMPA-SC (depot medroxyprogesterone acetate). After 6 
and 12 months of treatment the pain was reduced in up to 86 % of the 
women treated with elagolix compared to DMPA-SC17.  
Do to there peptide structure, potential adverse effects are histamine 
related. Thus, allergic reaction symptoms and hypersensitivity states 
could be fatal18. 
!
!
5. DANAZOL 
!
This drug was the first one approved by the FDA of the United State 
for the treatment of endometriosis in 197019. Chemically, it is an isoxazole 
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derivative of ethinyltestosterone and has a profound growth-inhibitory 
effect on an established human endometrial adenocarcinoma cell line, 
with isolated weak androgenic activity and no oestrogen or progestin 
effect2,20. This causes a high androgenic and low oestrogen environment, 
by directly inhibiting the mid-cycle urinary LH surge, causing an 
anovulatory state2. The amenorrhea side effect prevents more peritoneal 
seeding of Endometriosis and the low oestrogen state prevents growth of 
already present lesions1,2.  
 Other immunological effects of this drug include, decrease of serum 
immunoglobulin, decrease C3 complement, rise C4, decrease level of 
auto antibodies against phospholipids antigen, and decrease serum level 
of CA125. It also decrease IL-1 and TNF, (inflammatory cytokines), by 
production of monocytes , and suppresses macrophages and monocytes 
mediated cytotoxicity of target cells in women with mild disease1. This 
explains the use of danazol in inflammatory diseases such as fibrocystic 
breast disease, immune thrombocytopenic purport and hereditary 
angioedema1.  The starting dose is 400 mg per day 2 times orally, with 
increasing doses until pain release and amenorrhea develops 
(amenorrhea being the best indicator of the treatment effectiveness)1. In a 
6 months treatment period, pain relief is present in 90 % of patients2. 
Maximum dose reaches 800 mg per day in North America1. This limit is 
due to side effects of androgenic and hypo-oestrogenic state1. Negative 
side effects of this treatment include weight gain, fluid retention, hot 
flashes, fatigue, nausea, muscle cramps, emotional lability, acne, oily skin, 
which are all due to the hypo-oestrogenic state. Androgenic effects are 
hirsutism, acne, deepening of the voice which is non reversible1,2. The 
blood profile is also modified. Increase cholesterol and LDL and 
decreases HDL1,2. It is, therefore, contra-indicated in patients with 
hypertension, congestive heart failure and renal impairment functions 
(adding fluid retention effect). Patients with liver diseases also cannot 
benefit from this drug, as it is metabolised by this organ1. For long term 
treatment, liver enzymes have to be monitored repetitively. A potent 
contraception has to be used because Danazol causes masculinisation on 
the foetus1,2. Other routes of administration are in progress. A vaginal 
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danazol ring (1,5 mg) presented pain release in deep infiltrative 
endometriosis without the typical side effects of oral Danazol1. 
!
!
6. AROMATASE INHIBITOR 
!
Aromatase is an enzyme that converts testosterone to estradiol and 
androstenedione to estrone21. Inhibition of this enzyme results in hypo-
oestrogenic state. Aromatase activity is not detectable in normal 
endometrium and it has been shown to be expressed incorrectly in the 
biopsies of  endometrium of women suffering from endometriosis22. In 
case reports, 1 mg per day of anastrozole or 2.5 mg per day of letrozole, 
reduce pelvic pain2.  
A randomised trial evaluated the pain reduction in post operative women 
that underwent endometrial reduction, comparing GnHR agonist alone 
with GHR agonist joined with anastrozole2. Anastrozole, letrozole and 
triazole are the third generation of aromatase inhibitors. They are more 
selective, reversible and potent inhibitors with less sides effects than the 
first or second generation22. Aromatase inhibitors are also associated with 
several side effects associated with hypogonadal state like: -bone loss, a 
possible increased incidence of coronary heart disease and changes in 
cognitive function23. Most frequent side effects of third generation are 
hypoestrogenic  symptoms (vaginal dryness, hot flushes, headache, back 
pain and leg cramps)22. In case of deep infiltrating rectovaginal 
endometriosis, refractory to other medical or surgical treatment, clinicians 
can consider aromatase inhibitor in combination with oral contraceptive 
pills, progestagens or GnRH agonists7. But as for the treatment of non-
profond endometriosis, aromatase inhibitors should be considered after 
prescribing all other medical options are exhausted24.  
In addition, adding progestins or oral contraceptive pills will act as add-
back therapy to prevent reduction of bone demineralisation, thence, 
osteoporosis22. 
!
!
!
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7. SELECTIVE ESTROGEN RECEPTOR MODULATORS 
!
Regression of endometriosis tissue has been shown in vivo , in rat 
models, with a SERM called Raloxifene1. This SERM mimic oestrogen in 
decreasing bone resorption and increasing its density. It also decreases 
LDL6. It is, thus, prescribed to women suffering from osteoporosis6. They 
can be targeted towards the alpha or beta subunits of oestrogen. Alpha 
receptors are SERMs target in bone, mammary and endometrium, 
whereas beta receptors are SERMs target for expressing anti-
inflammatory action. One study conducted on endometriotic mice showed 
40 to 75 % of mice treated with beta-SERMs5. SERMs are also 
associated with side effect caused by depletion of oestrogen7. Warning is 
mandatory and usage of this drug is contra-indicated in pregnant women, 
during lactation and with history of an active thromboembolic disorder 
(cancer, thrombophilia)25  
!
!
8. SELECTIVE PROGESTERONE RECEPTOR MODULATORS 
!
This class of drug shows agonist and antagonist progesterone 
activities. If progesterone is present, they act like weak progestins and if 
progesterone is absent, they show weak anti-progestagenic activity26. The 
SPRM potentially induce reversible amenorrhea through selective 
inhibition of endometrial proliferation, a direct effect on endometrial 
vessels and suppression of prostaglandin production without the systemic 
effects of oestrogen deprivation25. One clinical trial composed of 130 
women experiences reduction of pelvic pain and dysmenorrhoea. No 
serious adverse effects were reported6. Common reported side effects 
include: headache, abdominal pain and tenderness26 
Other use of SPRM, in development, are endometrial cancer 
Cushing’s disease, Alzheimer disease and long-term contraception28 
!
!
!
!
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9.  IMMUNOMODULATORS 
!
As we explained in the pathogenesis part, altered immune functions 
play a role in endometriosis. A promising study on rodent and baboon 
model using a TNF-alpha inhibitor showed inhibition of the development of 
endometriosis6 
A study compared a new drug: bentamapimod against GnRH 
antagonist on rat to evaluate the regression of endometrial tissue. 
Bentamapimod is a c-Jun N-terminal Kinases inhibitor. This kinase has its 
place in immune reactions. The result of the study showed 48% 
regression the lesions with bentamapimod compared to 84% regression 
with the GnRH antagonist 29.  
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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PAIN MANAGEMENT 
!
Severe pain associated with endometriosis can frequently be 
managed by medical treatment while pain associated with deep infiltrative 
endometriosis could only be resolved by a surgical approach. 
Management of pain associated with endometriosis with targeted medical 
therapies may require one cycle for pain relief30 
!
!
1. NON STEROIDAL ANTI-INFLAMMATORY DRUGS 
!
Non steroidal ant-inflammatory drugs (NSAIDs) are first line 
treatment of pain associated with endometriosis. A small doubled blind 
cross over study compared naproxen versus placebo for the relief of 
pelvic pain. Ablation of pain was in 83% of the NSAIDs group compared to 
41 % in the placebo group31. NSAIDs inhibit a specific enzyme called 
cyclooxygenase (COX) which catalyse the formation of prostaglandin and 
thromboxane from a common precursor: arachidonic acid. By blocking this 
enzyme, less prostaglandin are produced and that is the goal we want to 
achieve. Two COXs enzymes are known. The second one is believed to 
be induced during an inflammatory state32. Selectively inhibiting COX, we 
will decrease gastro-intestinal side effect but studies did not prove any 
superiority of these drugs compared to one another. Since the main 
mechanism releasing pain is by blocking prostaglandin's formation, the 
drug must be taken before activation of this enzyme. Hence, NSAIDS are 
usually taken one to tow days before the menstrual cycle. Ibuprofen, one 
tablet every four to six hours. Naproxen sodium, one tablet every six to 
height hours33 
Side effects associated with NSAID are gastric ulcers, nausea, 
vomiting, diarrhoea and possible inhibition of ovulation. If the pain is not 
relieved by NSAIDs only, one’s can add paracetamol, or paracetamol+ 
codeine34. 
!
!
!
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2. OPOIDS 
!
Opioids related drugs bind on four different types of receptors in 
central and also on peripheral nerves: mu, kappa, delta and sigma. These 
receptors are the binding sites of many endogenous peptides which 
regulates pain, stress, temperature, respiration, endocrine activity, 
gastrointestinal activity, mood and motivation. The opioid drug can either 
act as an agonists or antagonists of the receptors. Using a full mu 
receptor agonist will cause pain relief, mood alteration, respiratory 
depression, decrease gastrointestinal motility, cough suppression, 
suppression of corticotrophin-releasing factor and adenocorticotropin 
hormone and myosis. Using a partial agonist, like buprenorphine, will 
cause less mood alteration. Sigma receptors mediate dysphoria, 
hallucinations, and psychosis; delta receptor agonism results in euphoria, 
analgesia, and seizures. Pain release effect differs depending on the 
administration routes. Intra venous action takes few minutes, intra-nasally 
10-15 minutes, intramuscularly 30-45 minutes, orally 90 minutes and two 
to four hours after dermal patches. Most common side-effects are: 
constipation, urinary retention, nausea, sedation, confusion, hallucination, 
sweating, xerostomia. The use of opioids may be associated with serious 
side effects that include: respiratory depression, seizures, hyperalgesia, 
myoclonus, delirium35. 
!
!
!
!
!
!
!
!
!
!
!
!
!
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ALTERNATIVE TREATMENT 
!
!
1. NATUROPATHY 
!
The naturopathic approach is mainly to provide a good liver function.  
A study made by the Institut of Perinatalogy in Mexico demonstrated 
the association between anti-oxydant and the pathology intensity. A group 
with anti-oxidant intake made from Vitamin C, E, Selenium and Zinc, was 
compared to a placebo group of women. No statistical difference was 
shown between those two groups, but when the data were stratified 
according to the pathology severity, it increases among lower anti-oxidant 
intake36. 
Chastberry increases progesterone effect from the ovaries. 1000 mg 
is recommended, taking daily in morning. It should not be added to the 
oral contraceptive pills, and is contra indicated during pregnancy. 
Vitamin E may alleviate with dysmenorrhea. It can also decrease the 
menstrual flow. Dosage is 400 - 500 unit daily, two days before 
menstruation and continuing the first three days of bleeding. 
Zinc tablet is common in Australia. It decreases pain but has many 
side effects (poor wound healing, poor appetite, lower immunity, acne, 
nausea, fatigue, it prevents body absorption of copper, manganese and 
molybdenum in food). Natural zinc is found in oyster, fish, nuts, dried peas 
and beans. Forty milligrams is used daily for the first month, for then being 
decreased to twenty milligrams. 
Magnesium tablet, naturally present in green vegetables, whole 
grain food, nuts and seeds, also decreases pelvic pain. In tablet, 100 mg 
is taken every two hours for less than two days. Side effects include: 
diarrhoea and bowel cramps37. 
!
!
2. PHYSIOTHERAPY 
!
There is a psychological component of pain that may create a 
negative circle. Pain leading to anxiety and depression, leads to 
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aggravating pain. Relaxation techniques and strengthening of pelvic floors 
muscles had shown positive feed back in women. Yoga will reduce 
dysmenorrhea by helping regulating the gate control pain mechanising in 
central nervous system by liberating endorphins. Reinforcing your pelvic 
floor will also help reducing dyspareunia33. 
!
!
3. TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR 
!
Transcutaneous electrical nerve stimulator (TENS) is designed to 
send slow voltage electrical current trough electrodes placed on the skin. 
The current stimulates the myelinated fibers which inhibit the 
unmyelinated C fibers. This prevents delivery of the “pain message” to the 
T cell present in the dorsal horn of the spinal, which will not trigger the 
pain area in the thalamus. The dorsal horn of the spinal cord is 
presynaptically inhibited. They also stimulate the body to produce more 
endorphins, enkephalin and dynorphins, that are natural pain antagonist. 
The use of this machine can be ambulatory. Each patient will try different 
intensities and frequencies to best suppress the pain. Each patient should 
also try different electrodes positions. There are three standards settings. 
The conventional, the acupuncture and the pulsed. Each of them has 
different frequency, intensity and discharge moment. It is up to the patient 
to decide which treatment provides with best results. The conventional 
way can be used all day long but the pain will generally recur when the 
current is turned off. The acupuncture way can be more effective than the 
conventional in inhibiting the pain despite turning off the voltage but the 
tolerance is debatable. The most frequent adverse effect if skin irritation. 
Contraindications  to TENS usage include: pacemaker and pregnancy. 
The overall pain relief is recorded to be up to 80 %, all indications mixed. 
This number drops to 20 % after few months of service making us believe 
that continuous nerve stimulation has a threshold38. 
!
!
!
!
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4. ACUPUNCTURE 
!
Acupuncture acts in many different ways. It activates endogenous 
descending pain inhibitory systems, deactivates brain areas that transmit 
pain related sensation, interacts between nociceptive impulses and 
somato-visceral reflexes, and induced the expectation of symptoms relief. 
We can it has physiological and psychological components. A meta-
analysis that included three studies of 99 women diagnosed with 
endometriosis explored the positive effect of acupuncture in endometriosis 
related pain. Similar approach was used in all studies by: 7 to 12 needle 
insertions per subject/ session, and 15 to 25 minutes of needle retention 
time. The needles were placed in the lower back/ pelvic-abdominal area, 
in the shank, feet, and hands. The number of sessions varied from 9 to 16 
with one to two treatments per week. In all three studies, patients rated 
their pain lower after acupuncture treatment39. 
!
!
5. DIET 
!
Deficiencies in nutrients can cause lipid metabolism disorders, 
oxidative stress and epigenetic abnormalities. The big picture is to avoid 
processed food and promote organic food. In processed food, we do not 
no what substance might be present (pesticides, colorants, preservatives, 
acidulants, stabilisers), and most of them are inflammatory. Red meat 
contains estradiol and estrange sulcate. Those contributes to high level of 
steroid in the blood. Food rich in omega 3 has anti-inflammatory effects. 
Only few studies concern the nutritional aspect related to endometriosis, 
but diet education seems to be a promising tool against it40 
!
!
6. HERBAL  
!
Herbal medication is described to be useful in the relief of 
endometriotic pain. It is also difficult to apply outside the Traditional 
Chinese Medicine41. Even though, phytotherapy is one of the most 
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popular form of complementary and alternative medication in the United 
States42. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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